A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin® (EU and US) in healthy male subjects-Reference-Cited by-同舟云学术

A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin® (EU and US) in healthy male subjects

Published:2018-07-26 Issue:10 Volume:84 Page:2352-2364
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Wynne Chris¹,Schwabe Christian²,Batra Sonica Sachdeva³^ORCID,Lopez-Lazaro Luis⁴,Kankanwadi Suresh⁴

Affiliation:

1. Christchurch Clinical Studies Trust Ltd.; 31 Tuam Street, Post Office Box 2856 Christchurch 8011 New Zealand

2. Auckland Clinical Studies Ltd.; ACS House, 3 Ferncroft Street Grafton New Zealand

3. Biologics; Dr. Reddy's Lab. Ltd.; Survey No. 47, Bachupally, Medchal Malkajgiri District, Telangana Hyderabad 500 090 India

4. Biologics; Dr. Reddy's Lab. SA; Elisabethenanlage 11 Basel 4051 Switzerland

Funder

Dr. Reddy's Laboratories Ltd.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13691/fullpdf

Reference29 articles.

1. Avastin ® (bevacizumab) prescribing information https://www.gene.com/download/pdf/avastin_prescribing.pdf

2. Avastin ® (bevacizumab) summary of product characteristics http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf

3. Angiogenesis in cancer, vascular, rheumatoid and other disease;Folkman;Nat Med,1995

4. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future;Sharma;Curr Cancer Drug Targets,2011

5. The role of vascular endothelial growth factor in angiogenesis;Ferrara;Acta Haematol,2001

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monoclonal antibody biosimilars for cancer treatment;iScience;2024-06

2. Regulatory Considerations of Biosimilars in Cancer;Biosimilars for Cancer Treatment;2024

3. Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab;Pharmacology Research & Perspectives;2023-11-02

4. Comparison of Efficacy and Safety of a Bevacizumab Biosimilar, in Combination with Chemotherapies, in Nonresectable Metastatic Colorectal Cancer and in Advanced Nonsquamous Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study;South Asian Journal of Cancer;2023-10-13

5. A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin®) in Healthy Chinese Males;Drugs in R&D;2023-05-29